Catalyst Pharmaceuticals (NASDAQ:CPRX) Upgraded by StockNews.com to “Strong-Buy” Rating

StockNews.com upgraded shares of Catalyst Pharmaceuticals (NASDAQ:CPRX) from a buy rating to a strong-buy rating in a research note published on Friday.

Several other analysts have also recently issued reports on CPRX. Stephens began coverage on Catalyst Pharmaceuticals in a research report on Monday, November 18th. They set an “overweight” rating and a $35.00 target price on the stock. Truist Financial increased their target price on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a research report on Monday, November 11th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $30.00 target price on shares of Catalyst Pharmaceuticals in a research report on Friday, November 8th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $31.14.

Catalyst Pharmaceuticals Stock Down 1.0 %

Shares of NASDAQ:CPRX opened at $21.31 on Friday. Catalyst Pharmaceuticals has a 52-week low of $13.12 and a 52-week high of $24.27. The stock has a market cap of $2.54 billion, a P/E ratio of 18.06, a price-to-earnings-growth ratio of 3.35 and a beta of 0.79. The business’s 50 day moving average is $21.80 and its 200 day moving average is $19.77.

Insider Transactions at Catalyst Pharmaceuticals

In related news, insider Steve Miller sold 50,000 shares of the firm’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $21.93, for a total value of $1,096,500.00. Following the completion of the transaction, the insider now owns 686,996 shares in the company, valued at $15,065,822.28. This trade represents a 6.78 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Molly Harper sold 17,500 shares of the firm’s stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $22.00, for a total value of $385,000.00. The disclosure for this sale can be found here. Insiders sold 79,500 shares of company stock valued at $1,754,140 in the last quarter. 11.00% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Catalyst Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CPRX. GAMMA Investing LLC raised its stake in Catalyst Pharmaceuticals by 62.1% in the 3rd quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 681 shares during the last quarter. nVerses Capital LLC purchased a new position in shares of Catalyst Pharmaceuticals during the 3rd quarter valued at about $50,000. Larson Financial Group LLC raised its stake in shares of Catalyst Pharmaceuticals by 27,218.2% during the 3rd quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock valued at $60,000 after buying an additional 2,994 shares during the last quarter. Meeder Asset Management Inc. purchased a new position in shares of Catalyst Pharmaceuticals during the 2nd quarter valued at about $70,000. Finally, Quantbot Technologies LP purchased a new position in shares of Catalyst Pharmaceuticals during the 3rd quarter valued at about $151,000. Hedge funds and other institutional investors own 79.22% of the company’s stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.